Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
postMONARCH: Abemaciclib Plus Fulvestrant vs Placebo Plus Fulvestrant in HR+, HER2- Advanced Breast Cancer After Prior CDK4/6 Inhibitor
2023-506771-10-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Abemaciclib plus fulvestrant with Placebo plus fulvestrant (2 arms). Primary endpoint: Progression-Free Survival (PFS). Planned start Mar 2022; status: authorised.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-506771-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506771-10-00.